{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "A campaign for a drug that aims to restore lost libido accuses the Food and Drug Administration of gender bias for approving Viagra and 25 other drugs to help men have sex, but none for women.", "headline": {"main": "\u2018Viagra for Women\u2019 Gets Push for F.D.A. Approval", "print_headline": "The F.D.A. Is Pressed on \u2018Women\u2019s Viagra\u2019"}, "abstract": "Even the Score, campaign backed by Sprout Pharmaceuticals and some women's groups, seeks to show that FDA is displaying gender bias by not approving drug flibanserin, which restores libido in women; Sprout is maker of the drug, and campaign has highlighted how FDA has approved numerous drugs to help men have sex, but none for women.", "print_page": "1", "word_count": "1500", "_id": "556bb42879881019f18de4ac", "snippet": "A campaign for a drug that aims to restore lost libido accuses the Food and Drug Administration of gender bias for approving Viagra and 25 other drugs to help men have sex, but none for women.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2015/06/01/business/groups-press-fda-to-approve-womens-viagra.html", "multimedia": [{"subtype": "wide", "url": "images/2015/06/01/business/01libido/01libido-thumbWide.jpg", "height": 126, "width": 190, "legacy": {"wide": "images/2015/06/01/business/01libido/01libido-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "type": "image"}, {"subtype": "xlarge", "url": "images/2015/06/01/business/01libido/01libido-articleLarge.jpg", "height": 456, "width": 600, "legacy": {"xlargewidth": "600", "xlarge": "images/2015/06/01/business/01libido/01libido-articleLarge.jpg", "xlargeheight": "456"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2015/06/01/business/01libido/01libido-thumbStandard.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2015/06/01/business/01libido/01libido-thumbStandard.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"value": "Food and Drug Administration", "is_major": "Y", "rank": "1", "name": "organizations"}, {"value": "Sex", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Women and Girls", "is_major": "Y", "rank": "3", "name": "subject"}, {"value": "Sprout Pharmaceuticals Inc", "is_major": "Y", "rank": "4", "name": "organizations"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "5", "name": "subject"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2015-06-01T00:00:00Z", "section_name": "Business Day"}, {"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "Identifying which patients are likely to benefit from expensive treatments such as Opdivo, Yervoy and Keytruda could save money and prevent side effects.", "headline": {"main": "Doctors Seek Test for Deploying New Life-Extending Cancer Drugs", "print_headline": "Specialists Seeking Tests for Deploying New Life-Extending Cancer Drugs"}, "abstract": "Doctors are underscoring need for test that can determine whether expensive immune-boosting drugs like Opdivo and Yervoy will work on cancer patients in advance, as drugs help only minority of patients, but work exceedingly well; challenges of creating test are both ethical and scientific; importance of test has been laid out in study published in New England Journal of Medicine.", "print_page": "3", "word_count": "1097", "_id": "556af0d279881001e9592a9f", "snippet": "Identifying which patients are likely to benefit from expensive treatments such as Opdivo, Yervoy and Keytruda could save money and prevent side effects.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2015/06/01/business/doctors-seek-test-for-deploying-new-life-extending-cancer-drugs.html", "multimedia": [{"subtype": "wide", "url": "images/2015/05/31/business/01SKIN-web/01SKIN-web-thumbWide.jpg", "height": 126, "width": 190, "legacy": {"wide": "images/2015/05/31/business/01SKIN-web/01SKIN-web-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "type": "image"}, {"subtype": "xlarge", "url": "images/2015/05/31/business/01SKIN-web/01SKIN-web-articleLarge.jpg", "height": 401, "width": 600, "legacy": {"xlargewidth": "600", "xlarge": "images/2015/05/31/business/01SKIN-web/01SKIN-web-articleLarge.jpg", "xlargeheight": "401"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2015/05/31/business/01SKIN-web/01SKIN-web-thumbStandard.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2015/05/31/business/01SKIN-web/01SKIN-web-thumbStandard.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Cancer", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Tests (Medical)", "is_major": "Y", "rank": "3", "name": "subject"}, {"value": "New England Journal of Medicine", "is_major": "Y", "rank": "4", "name": "organizations"}, {"value": "Lung Cancer", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Immune System", "is_major": "N", "rank": "6", "name": "subject"}, {"value": "Memorial Sloan-Kettering Cancer Center", "is_major": "N", "rank": "7", "name": "organizations"}, {"value": "Tumors", "is_major": "N", "rank": "8", "name": "subject"}, {"value": "Melanomas", "is_major": "N", "rank": "9", "name": "subject"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2015-06-01T00:00:00Z", "section_name": "Business Day"}], "meta": {"hits": 12, "offset": 10, "time": 30}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}